BioMarin Announces Incremental Progress On Biologics License Application Review For Valoctocogene Roxaparvovec AAV Gene Therapy For Adults With Severe Hemophilia A Program
FDA Pre-Licensure Inspection of Gene Therapy Manufacturing Facility Scheduled
FDA Requests Submission of Upcoming 3-Year Data Analysis from Phase 3 GENEr8-1 Study
Current PDUFA Target Action Date of March 31, 2023,